- Joined
- 3 May 2019
- Posts
- 6,195
- Reactions
- 9,695
Are you talking in your sleep there Tech? Haha.
As you have mentioned this stock in your sleep, I put it in a watchlist. Now popping.
ZLD - Zelira Therapeutics
- Thread starter YOUNG_TRADER
- Start date
As you have mentioned this stock in your sleep, I put it in a watchlist. Now popping.
tinhat
Pocket Calculator Operator
- Joined
- 1 May 2009
- Posts
- 1,756
- Reactions
- 768
If the doors of perception were cleansed every thing would appear to man as it is, Infinite.
tinhat
Pocket Calculator Operator
- Joined
- 1 May 2009
- Posts
- 1,756
- Reactions
- 768
Where are the posts from last year? Have I followed the wrong thread? I tipped that the chart was toppy but my thoughts are not always allowed.
Dona Ferentes
A little bit OC⚡DC
- Joined
- 11 January 2016
- Posts
- 15,199
- Reactions
- 20,631
and on 15 Feb 2021
usually a sign the last incarnation has washed up on the shores of investor indifference.
"Richard has been instrumental in helping facilitate Zelira’s merger and transition to a global revenue generating company. He has overseen the development of a pipeline of clinically validated products that recently launched on the Australian market and are now poised to enter global markets. With these outcomes successfully delivered, the time is right to position the Company for future growth by transitioning to a US-based leadership team. This will allow Zelira to optimise its exposure to the rapidly expanding US cannabis sector while also continuing to grow its revenues in ex-USA markets. We thank Richard for all his efforts in taking Zelira’s ex-US operations forward during his tenure and wish him well in his future career.”
- Joined
- 2 May 2007
- Posts
- 4,698
- Reactions
- 2,908
thought to look into this ugly duckling
Lucky charms for ZLD
Ilera holds about 44 pc and Jason holds about 6 pc
Lucky charms for ZLD
Ilera holds about 44 pc and Jason holds about 6 pc
Dona Ferentes
A little bit OC⚡DC
- Joined
- 11 January 2016
- Posts
- 15,199
- Reactions
- 20,631
a year sine the last post; and the chart / entrail examiners would like this one.
$1.00 in the first week of July and $3.23 some six days later.
The Company was in the process of preparing an announcement in relation to this matter, and was relying on Listing Rule 3.1A.2 not to announce that information under Listing Rule 3.1 on the basis that a very limited number of employees withing the Company were in possession of the information and the Company considered the information to be confidential
Upon the ASX forming the view that the information ceased to be confidential a trading halt was requested.
Notwithstanding the concurrent timing, the Board’s view is that the recent increase in share price was most likely driven by an increase in small volume buyers being met by a reduction in small volume sellers that those seen over recent weeks. The Company considered that the movement in share price indicated that investors had begun to identify the unique investment opportunity Zelira’s multiple shots on goal strategy presents as opposed to directly being a response to the news referred to in question 1 above
$1.00 in the first week of July and $3.23 some six days later.
Yes, the Company is very recently in possession of German regulatory authority BfArM results with respect to its clinically validated cannabinoid-based insomnia medication, Zenivol®.
The Company was in the process of preparing an announcement in relation to this matter, and was relying on Listing Rule 3.1A.2 not to announce that information under Listing Rule 3.1 on the basis that a very limited number of employees withing the Company were in possession of the information and the Company considered the information to be confidential
Upon the ASX forming the view that the information ceased to be confidential a trading halt was requested.
Notwithstanding the concurrent timing, the Board’s view is that the recent increase in share price was most likely driven by an increase in small volume buyers being met by a reduction in small volume sellers that those seen over recent weeks. The Company considered that the movement in share price indicated that investors had begun to identify the unique investment opportunity Zelira’s multiple shots on goal strategy presents as opposed to directly being a response to the news referred to in question 1 above
- Joined
- 12 January 2008
- Posts
- 7,176
- Reactions
- 17,762
I resemble that description.
I did look at ZLD after the recent price spikes. The "entrails" looked atypical with a gap at the end of April.
ZLD has undergone a consolidation of 175:1 which is a strange number but it was done in conjunction with the HHI merger.
Prices of other medicinal cannabis companies are rising as well (AGH, BOT, CAN, CGB, ECS, EXL, IDT, LGP, MDC).
Something's in the air (other than smoke).
- Joined
- 3 May 2019
- Posts
- 6,195
- Reactions
- 9,695
Zelira’s diabetic nerve pain drug outperforms Big Pharma drug; successful clinical trial against multi-billion-dollar Lyrica®
Dona Ferentes
A little bit OC⚡DC
- Joined
- 11 January 2016
- Posts
- 15,199
- Reactions
- 20,631
The best biotech mover by far in May was Zelira, which almost tripled after announcing that its diabetic nerve pain drug outperforms multi-billion dollar Big Pharma drug, Lyrica – achieving a significant reduction in NRS pain scores, indicating a decrease in symptom severity.
ZLT-L-007 was found to be safe and well-tolerated, meeting the primary endpoint for safety with no Serious Adverse Events (SAE). The study also met its secondary endpoints, including significant decreases in Visual Analog Scale (VAS) and Short-form McGill scores, among others.
The company plans to evaluate the further progression of ZLT-L-007 into formal FDA clinical trials.
Looks impressive, but quickly giving it up in June.
And over 5 years, how much has been burnt to get to today?
ZLT-L-007 was found to be safe and well-tolerated, meeting the primary endpoint for safety with no Serious Adverse Events (SAE). The study also met its secondary endpoints, including significant decreases in Visual Analog Scale (VAS) and Short-form McGill scores, among others.
The company plans to evaluate the further progression of ZLT-L-007 into formal FDA clinical trials.
Looks impressive, but quickly giving it up in June.
And over 5 years, how much has been burnt to get to today?
Last edited:
- Joined
- 3 May 2019
- Posts
- 6,195
- Reactions
- 9,695
Will be interesting to see how this goes over the next few trade days from a TA angle.
Anyone holding the tiger by the tail?
Anyone holding the tiger by the tail?
- Joined
- 12 January 2008
- Posts
- 7,176
- Reactions
- 17,762
Nah, we've seen this before.
Is it different this time? LOL
Is it different this time? LOL